Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

The European Commission approved Alnylam's Amvuttra for treating wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM), expanding its prior EU approval for hereditary transthyretin amyloidosis with polyneuropathy. This approval, based on positive HELIOS-B trial data showing reduced mortality and cardiovascular events, makes Amvuttra the first RNAi therapy approved in the EU for both ATTR-CM and hATTR-PN and is expected to boost the company's revenue, building on already strong Amvuttra sales that contributed to Alnylam's better-than-expected Q1 2025 results.

Analysis

Alnylam Pharmaceuticals (ALNY) has secured a significant regulatory milestone with the European Commission's (EC) approval for the label expansion of its RNAi therapeutic, Amvuttra, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). This approval was based on compelling positive data from the late-stage HELIOS-B study, which successfully met all 10 pre-specified primary and secondary endpoints, demonstrating statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as notable improvements in functional capacity, health status, quality of life, and heart failure symptoms. This EC decision establishes Amvuttra as the first and only RNAi therapeutic approved in the European Union for both ATTR-CM and hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). The drug's quarterly subcutaneous administration offers a distinct advantage over existing therapies like tafamidis, which require daily oral dosing. This European approval follows similar regulatory green lights in the United States and Brazil earlier in 2025, considerably expanding Amvuttra's global market reach. Alnylam's stock has reflected this positive momentum, rallying 29.1% year-to-date, in sharp contrast to the broader industry's 0.9% decline. The company reported better-than-expected first-quarter 2025 results, with both earnings and revenues surpassing estimates, largely fueled by growing Amvuttra sales. The recent label expansions in the U.S. and now the EU are poised to further accelerate revenue growth in the upcoming quarters. The overall sentiment surrounding this development is strongly positive, with a high market impact score, underscoring its importance for Alnylam's outlook.

Key Decisions for Investors

• The EC approval for Amvuttra in ATTR-CM significantly enhances Alnylam's growth prospects and competitive positioning, potentially justifying a re-evaluation of revenue projections given the expanded patient population and the drug's differentiated clinical profile.
• Investors should closely monitor the commercial launch and market penetration of Amvuttra for ATTR-CM in the EU, as its adoption rate relative to existing treatments will be a critical driver for future earnings and sustaining the stock's strong year-to-date performance of a 29.1% rally.
• While the regulatory and clinical news for Amvuttra is unequivocally positive, Alnylam currently holds a Zacks Rank #3 (Hold); therefore, investors should assess if the current stock valuation fully reflects these recent advancements or if further upside is contingent on seamless commercial execution and continued sales momentum in the newly approved indication.